Naxitamab for high-risk or relapsed neuroblastoma in children
Treatments studied
Part of Cancer clinical trials.
This trial tests a targeted antibody called naxitamab (hu3F8) for children with high-risk neuroblastoma that has come back or is hard to treat. It aims to see if this therapy can help shrink or control the cancer with an acceptable safety profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child has been diagnosed with high-risk neuroblastoma (including relapsed or hard-to-treat forms).
- You are at least 1 year old.
- If you are sexually active, you agree to use effective birth control during treatment.
- If you have started menstruating, you must have a negative pregnancy test and not be pregnant or breastfeeding.
- You have not had a severe allergic reaction to anti-GD2 antibodies or GM-CSF in the past.
- You are not currently taking another experimental drug (or have taken one in the last 4 weeks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for children with high-risk neuroblastoma, a type of nerve cell cancer. It tests adding a new medicine called Naxitamb to standard induction therapy to see if it works better. High-risk means the cancer is advanced or has certain aggressive features.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This Phase 2 trial tests whether adding a drug called naxitamab to standard early (frontline) treatment improves outcomes for children with high-risk neuroblastoma. It may help by helping the immune system better target the cancer during initial induction therapy.
This trial tests a combination of naxitamab, GM-CSF, and isotretinoin as maintenance therapy for children with high-risk neuroblastoma who have achieved their first complete response after initial treatment. The goal is to help keep the cancer from coming back.
This trial tests giving a combination of naxitamab, irinotecan, and temozolomide for a longer period to people whose neuroblastoma has come back or hasn't responded to standard treatments. The goal is to see if this approach is safe and effective.
This trial tests a combination of two drugs (tipifarnib and naxitamab) for children and young adults with neuroblastoma that has come back or hasn't responded to standard treatments. The goal is to see if this new combination can help shrink or control the cancer.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.